{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T16:12:22Z","timestamp":1788970342657,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["HEC Forum"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Ketamine has emerged as an important intervention in contemporary psychiatry, yet its acute dissociative effects remain ethically under-theorized. Clinical approaches often frame dissociation as either a liability to minimize or a therapeutic feature to promote, but both views oversimplify a context-dependent phenomenon. We propose that ketamine-induced dissociation is better understood as an ethically salient signal whose significance is shaped by patient vulnerability, dosing, preparatory framing, interpersonal support, and post-session integration. Using a framework grounded in beneficence and non-maleficence, we conceptualize dissociation not as a neutral side effect but as a predictable alteration of subjectivity that may orient patients toward harm or therapeutic possibility. We distinguish two clinically meaningful trajectories: the dysphoric trajectory of dissociative experience, characterized by threat appraisal and foreseeable psychological harm, and the integrative trajectory of dissociative experience, characterized by meaningful or generative appraisal that may permit emotional reappraisal and meaning-making. We advance a dual-trajectory model in which clinical context shapes these outcomes, supporting proportionate safeguards rather than categorical exclusion and informing consent, risk assessment, and intervention design.<\/jats:p>","DOI":"10.1007\/s10730-026-09611-x","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:30:06Z","timestamp":1788967806000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ketamine-Induced Dissociation as an Ethical Signal, Not a Side Effect: Context as the Determinant of Clinical Duties Under Beneficence and Non-maleficence"],"prefix":"10.1007","author":[{"given":"Gun","family":"Moon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Noto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Shuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Pilkington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"9611_CR1","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.jad.2019.11.028","volume":"263","author":"EE Acevedo-Diaz","year":"2020","unstructured":"Acevedo-Diaz, E. E., Cavanaugh, G. W., Greenstein, D., Kraus, C., Kadriu, B., Zarate, C. A., & Park, L. T. (2020). Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression. Journal of Affective Disorders, 263, 568\u2013575. https:\/\/doi.org\/10.1016\/j.jad.2019.11.028","journal-title":"Journal Of Affective Disorders"},{"issue":"4","key":"9611_CR2","doi-asserted-by":"publisher","first-page":"100316","DOI":"10.1016\/j.bpsgos.2024.100316","volume":"4","author":"J Aepfelbacher","year":"2024","unstructured":"Aepfelbacher, J., Panny, B., & Price, R. B. (2024). Experiences of awe mediate ketamine\u2019s antidepressant effects: Findings from a randomized controlled trial in treatment-resistant depression. Biological Psychiatry: Global Open Science, 4(4), 100316. https:\/\/doi.org\/10.1016\/j.bpsgos.2024.100316","journal-title":"Biol Psychiatry Glob Open Sci"},{"issue":"1","key":"9611_CR3","doi-asserted-by":"publisher","first-page":"6431","DOI":"10.1038\/s41467-020-20190-4","volume":"11","author":"ED Ballard","year":"2020","unstructured":"Ballard, E. D., & Zarate, C. A. (2020). The role of dissociation in ketamine\u2019s antidepressant effects. Nature Communications, 11(1), 6431. https:\/\/doi.org\/10.1038\/s41467-020-20190-4","journal-title":"Nature Communications"},{"key":"9611_CR4","unstructured":"Beauchamp, T. L., & Childress, J. F. (1979). Principles of biomedical ethics. Oxford University Press."},{"issue":"5","key":"9611_CR5","doi-asserted-by":"publisher","first-page":"e204693","DOI":"10.1001\/jamanetworkopen.2020.4693","volume":"3","author":"K Beck","year":"2020","unstructured":"Beck, K., Hindley, G., Borgan, F., Ginestet, C., McCutcheon, R., Brugger, S., Driesen, N., Ranganathan, M., D\u2019Souza, D. C., Taylor, M., et al. (2020). Association of ketamine with psychiatric symptoms and implications for its therapeutic use and for understanding Schizophrenia: A systematic review and meta-analysis. JAMA Open Network, 3(5), e204693. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.4693","journal-title":"JAMA Netw Open"},{"issue":"12","key":"9611_CR6","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1002\/jclp.23576","volume":"79","author":"ID Boreham","year":"2023","unstructured":"Boreham, I. D., & Schutte, N. S. (2023). The relationship between purpose in life and depression and anxiety: A meta-analysis. Journal of Clinical Psychology, 79(12), 2736\u20132767. https:\/\/doi.org\/10.1002\/jclp.23576","journal-title":"Journal Of Clinical Psychology"},{"issue":"7","key":"9611_CR7","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1007\/s00213-023-06388-6","volume":"240","author":"JJ Breeksema","year":"2023","unstructured":"Breeksema, J. J., Niemeijer, A., Kuin, B., Veraart, J., Vermetten, E., Kamphuis, J., van den Brink, W., & Schoevers, R. (2023). Phenomenology and therapeutic potential of patient experiences during oral esketamine treatment for treatment-resistant depression: An interpretative phenomenological study. Psychopharmacology (Berl), 240(7), 1547\u20131560. https:\/\/doi.org\/10.1007\/s00213-023-06388-6","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"9611_CR8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1023\/A:1024465317902","volume":"11","author":"JD Bremner","year":"1998","unstructured":"Bremner, J. D., Krystal, J. H., Putnam, F. W., Southwick, S. M., Marmar, C., Charney, D. S., & Mazure, C. M. (1998). Measurement of dissociative states with the clinician-administered dissociative states scale (CADSS). Journal of Traumatic Stress, 11(1), 125\u2013136. https:\/\/doi.org\/10.1023\/A:1024465317902","journal-title":"Journal Of Traumatic Stress"},{"issue":"6","key":"9611_CR9","doi-asserted-by":"publisher","first-page":"410","DOI":"10.3109\/15622975.2016.1139747","volume":"18","author":"MD Cooper","year":"2017","unstructured":"Cooper, M. D., Rosenblat, J. D., Cha, D. S., Lee, Y., Kakar, R., & McIntyre, R. S. (2017). Strategies to mitigate dissociative and psychotomimetic effects of ketamine in the treatment of major depressive episodes: A narrative review. The World Journal of Biological Psychiatry, 18(6), 410\u2013423. https:\/\/doi.org\/10.3109\/15622975.2016.1139747","journal-title":"World J Biol Psychiatry Off J World Fed Soc Biol Psychiatry"},{"issue":"3","key":"9611_CR10","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1097\/ALN.0b013e3181ed09a2","volume":"113","author":"EF Domino","year":"2010","unstructured":"Domino, E. F. (2010). Taming the ketamine tiger, 1965. Anesthesiology, 113(3), 678\u2013684. https:\/\/doi.org\/10.1097\/ALN.0b013e3181ed09a2","journal-title":"Anesthesiology"},{"issue":"2","key":"9611_CR11","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/02791072.2019.1587556","volume":"51","author":"J Dore","year":"2019","unstructured":"Dore, J., Turnipseed, B., Dwyer, S., Turnipseed, A., Andries, J., Ascani, G., Monnette, C., Huidekoper, A., Strauss, N., & Wolfson, P. (2019). Ketamine assisted psychotherapy (KAP): Patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy. Journal of Psychoactive Drugs, 51(2), 189\u2013198. https:\/\/doi.org\/10.1080\/02791072.2019.1587556","journal-title":"Journal Of Psychoactive Drugs"},{"issue":"11","key":"9611_CR12","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/mp.2012.194","volume":"18","author":"NR Driesen","year":"2013","unstructured":"Driesen, N. R., McCarthy, G., Bhagwagar, Z., Bloch, M., Calhoun, V., D\u2019Souza, D. C., Gueorguieva, R., He, G., Ramachandran, R., Suckow, R. F., et al. (2013). Relationship of resting brain hyperconnectivity and schizophrenia-like symptoms produced by the NMDA receptor antagonist ketamine in humans. Molecular Psychiatry, 18(11), 1199\u20131204. https:\/\/doi.org\/10.1038\/mp.2012.194","journal-title":"Molecular Psychiatry"},{"key":"9611_CR13","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.2147\/JPR.S360733","volume":"15","author":"SJ Drozdz","year":"2022","unstructured":"Drozdz, S. J., Goel, A., McGarr, M. W., Katz, J., Ritvo, P., Mattina, G. F., Bhat, V., Diep, C., & Ladha, K. S. (2022). Ketamine assisted psychotherapy: A systematic narrative review of the literature. Journal of Pain Research, 15, 1691\u20131706. https:\/\/doi.org\/10.2147\/JPR.S360733","journal-title":"J Pain Res"},{"key":"9611_CR14","doi-asserted-by":"publisher","first-page":"112629","DOI":"10.1016\/j.bbr.2020.112629","volume":"392","author":"M Grabski","year":"2020","unstructured":"Grabski, M., Borissova, A., Marsh, B., Morgan, C. J. A., & Curran, H. V. (2020). Ketamine as a mental health treatment: Are acute psychoactive effects associated with outcomes? A systematic review. Behavioural Brain Research, 392, 112629. https:\/\/doi.org\/10.1016\/j.bbr.2020.112629","journal-title":"Behavioural Brain Research"},{"key":"9611_CR15","doi-asserted-by":"publisher","first-page":"100079","DOI":"10.1016\/j.jadr.2021.100079","volume":"4","author":"C Griffiths","year":"2021","unstructured":"Griffiths, C., Walker, K., Reid, I., da Silva, K. M., & O\u2019Neill-Kerr, A. (2021). A qualitative study of patients\u2019 experience of ketamine treatment for depression: The \u2018Ketamine and me\u2019 project. Journal of Affective Disorders Reports, 4, 100079. https:\/\/doi.org\/10.1016\/j.jadr.2021.100079","journal-title":"J Affect Disord Rep"},{"issue":"10","key":"9611_CR16","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1111\/add.70073","volume":"120","author":"RE Harding","year":"2025","unstructured":"Harding, R. E., Barton, T., Niepceron, M., Harris, E., Bennett, E., Gent, E., Fraser, F., & Morgan, C. J. A. (2025). The landscape of ketamine use disorder: Patient experiences and perspectives on current treatment options. Addiction, 120(10), 1970\u20131979. https:\/\/doi.org\/10.1111\/add.70073","journal-title":"Addiction"},{"key":"9611_CR17","doi-asserted-by":"publisher","unstructured":"Hayes, S. C., Wilson, K. G., Gifford, E. V., Follette, V. M., & Strosahl, K. (1996). Experimental avoidance and behavioral disorders: A functional dimensional approach to diagnosis and treatment. Journal of Consulting and Clinical Psychology, 64(6), 1152\u20131168. https:\/\/doi.org\/10.1037\/0022-006X.64.6.1152","DOI":"10.1037\/0022-006X.64.6.1152"},{"issue":"5","key":"9611_CR18","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1007\/s00406-023-01732-5","volume":"275","author":"Y Jiang","year":"2025","unstructured":"Jiang, Y., Du, Z., Shen, Y., Zhou, Q., & Zhu, H. (2025). The correlation of Esketamine with specific adverse events: A deep dive into the FAERS database. European Archives of Psychiatry and Clinical Neuroscience, 275(5), 1373\u20131381. https:\/\/doi.org\/10.1007\/s00406-023-01732-5","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"3","key":"9611_CR19","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","volume":"51","author":"JH Krystal","year":"1994","unstructured":"Krystal, J. H., Karper, L. P., Seibyl, J. P., Freeman, G. K., Delaney, R., Bremner, J. D., Heninger, G. R., Bowers, M. B., & Charney, D. S. (1994). Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Archives of General Psychiatry, 51(3), 199\u2013214. https:\/\/doi.org\/10.1001\/archpsyc.1994.03950030035004","journal-title":"Archives Of General Psychiatry"},{"key":"9611_CR20","doi-asserted-by":"publisher","first-page":"114231","DOI":"10.1016\/j.psychres.2021.114231","volume":"306","author":"TT Le","year":"2021","unstructured":"Le, T. T., Di Vincenzo, J. D., Teopiz, K. M., Lee, Y., Cha, D. S., Lui, L. M. W., Rodrigues, N. B., Ho, R. C., Cao, B., Lin, K., et al. (2021). Ketamine for psychotic depression: An overview of the glutamatergic system and ketamine\u2019s mechanisms associated with antidepressant and psychotomimetic effects. Psychiatry Research, 306, 114231. https:\/\/doi.org\/10.1016\/j.psychres.2021.114231","journal-title":"Psychiatry Research"},{"issue":"2","key":"9611_CR21","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.jaclp.2023.11.687","volume":"65","author":"C Louka","year":"2024","unstructured":"Louka, C., & Chiao, S. (2024). Intravenous ketamine exacerbating symptoms of acute stress disorder: A case report and systematized review of existing literature. Journal of the Academy of Consultation-Liaison Psychiatry, 65(2), 204\u2013213. https:\/\/doi.org\/10.1016\/j.jaclp.2023.11.687","journal-title":"J Acad Consult-Liaison Psychiatry"},{"issue":"3","key":"9611_CR22","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S0893-133X(97)00036-5","volume":"17","author":"AK Malhotra","year":"1997","unstructured":"Malhotra, A. K., Pinals, D. A., Adler, C. M., Elman, I., Clifton, A., Pickar, D., & Breier, A. (1997). Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology, 17(3), 141\u2013150. https:\/\/doi.org\/10.1016\/S0893-133X(97)00036-5","journal-title":"Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol"},{"issue":"1","key":"9611_CR23","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1177\/02698811221140011","volume":"37","author":"M Marguilho","year":"2023","unstructured":"Marguilho, M., Figueiredo, I., & Castro-Rodrigues, P. (2023). A unified model of ketamine\u2019s dissociative and psychedelic properties. Journal of Psychopharmacology, 37(1), 14\u201332. https:\/\/doi.org\/10.1177\/02698811221140011","journal-title":"J Psychopharmacol Oxf Engl"},{"key":"9611_CR24","doi-asserted-by":"publisher","first-page":"1610335","DOI":"10.3389\/fpsyt.2025.1610335","volume":"16","author":"C Miller","year":"2025","unstructured":"Miller, C., Lopes, B., & McCurdy, A. (2025). The collective lie in ketamine therapy: A call to realign clinical practice with neurobiology. Frontiers in Psychiatry, 16, 1610335. https:\/\/doi.org\/10.3389\/fpsyt.2025.1610335","journal-title":"Frontiers In Psychiatry"},{"issue":"1","key":"9611_CR25","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/sj.npp.1300342","volume":"29","author":"CJA Morgan","year":"2004","unstructured":"Morgan, C. J. A., Mofeez, A., Brandner, B., Bromley, L., & Curran, H. V. (2004). Acute effects of ketamine on memory systems and psychotic symptoms in healthy volunteers. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology, 29(1), 208\u2013218. https:\/\/doi.org\/10.1038\/sj.npp.1300342","journal-title":"Neuropsychopharmacology : Official Publication Of The American College Of Neuropsychopharmacology"},{"issue":"9","key":"9611_CR26","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1017\/S0033291707002450","volume":"38","author":"CJA Morgan","year":"2008","unstructured":"Morgan, C. J. A., Rees, H., & Curran, H. V. (2008). Attentional bias to incentive stimuli in frequent ketamine users. Psychological Medicine, 38(9), 1331\u20131340. https:\/\/doi.org\/10.1017\/S0033291707002450","journal-title":"Psychological Medicine"},{"key":"9611_CR27","doi-asserted-by":"publisher","first-page":"710338","DOI":"10.3389\/fpsyt.2021.710338","volume":"12","author":"S-A Muscat","year":"2021","unstructured":"Muscat, S-A., Hartelius, G., Crouch, C. R., & Morin, K. W. (2021). An integrative approach to ketamine therapy may enhance multiple dimensions of efficacy: Improving therapeutic outcomes with treatment resistant depression. Frontiers in Psychiatry, 12, 710338. https:\/\/doi.org\/10.3389\/fpsyt.2021.710338","journal-title":"Frontiers In Psychiatry"},{"issue":"3","key":"9611_CR28","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1353\/ppp.2021.0032","volume":"28","author":"T Noorani","year":"2021","unstructured":"Noorani, T. (2021). Containment matters: Set and setting in contemporary psychedelic psychiatry. Philosophy, Psychiatry, & Psychology, 28(3), 201\u2013216. https:\/\/doi.org\/10.1353\/ppp.2021.0032","journal-title":"Philos Psychiatry Psychol"},{"key":"9611_CR29","unstructured":"Nuffield Council on Bioethics. (2015). Children and clinical research: Ethical issues. Nuffield Council on Bioethics."},{"issue":"3","key":"9611_CR30","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","volume":"10","author":"JE Overall","year":"1962","unstructured":"Overall, J. E., & Gorham, D. R. (1962). The brief psychiatric rating scale. Psychological Reports, 10(3), 799\u2013812. https:\/\/doi.org\/10.2466\/pr0.1962.10.3.799","journal-title":"Psychological Reports"},{"key":"9611_CR31","doi-asserted-by":"publisher","first-page":"46421","DOI":"10.1038\/srep46421","volume":"7","author":"MM Schartner","year":"2017","unstructured":"Schartner, M. M., Carhart-Harris, R. L., Barrett, A. B., Seth, A. K., & Muthukumaraswamy, S. D. (2017). Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin. Scientific Reports, 7, 46421. https:\/\/doi.org\/10.1038\/srep46421","journal-title":"Scientific Reports"},{"issue":"9","key":"9611_CR32","doi-asserted-by":"publisher","first-page":"e44799","DOI":"10.1371\/journal.pone.0044799","volume":"7","author":"M Scheidegger","year":"2012","unstructured":"Scheidegger, M., Walter, M., Lehmann, M., Metzger, C., Grimm, S., Boeker, H., Boesiger, P., Henning, A., & Seifritz, E. (2012). Ketamine decreases resting state functional network connectivity in healthy subjects: Implications for antidepressant drug action. PloS One, 7(9), e44799. https:\/\/doi.org\/10.1371\/journal.pone.0044799","journal-title":"PloS One"},{"issue":"1","key":"9611_CR33","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S2215-0366(17)30272-9","volume":"5","author":"B Short","year":"2018","unstructured":"Short, B., Fong, J., Galvez, V., Shelker, W., & Loo, C. K. (2018). Side-effects associated with ketamine use in depression: A systematic review. Lancet Psychiatry, 5(1), 65\u201378. https:\/\/doi.org\/10.1016\/S2215-0366(17)30272-9","journal-title":"Lancet Psychiatry"},{"issue":"8","key":"9611_CR34","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1177\/0269881121998321","volume":"35","author":"RL Sumner","year":"2021","unstructured":"Sumner, R. L., Chacko, E., McMillan, R., Spriggs, M. J., Anderson, C., Chen, J., French, A., Jung, S., Rajan, A., Malpas, G., et al. (2021). A qualitative and quantitative account of patient\u2019s experiences of ketamine and its antidepressant properties. Journal of Psychopharmacology, 35(8), 946\u2013961. https:\/\/doi.org\/10.1177\/0269881121998321","journal-title":"J Psychopharmacol Oxf Engl"},{"issue":"1","key":"9611_CR35","doi-asserted-by":"publisher","first-page":"e13425","DOI":"10.1111\/inm.13425","volume":"34","author":"M Trimmel","year":"2025","unstructured":"Trimmel, M., Renner, A., & Kaltenboeck, A. (2025). How do people who undergo ketamine treatment for a psychiatric problem subjectively experience this intervention? A meta-synthesis of qualitative studies. International Journal of Mental Health Nursing, 34(1), e13425. https:\/\/doi.org\/10.1111\/inm.13425","journal-title":"International Journal Of Mental Health Nursing"},{"issue":"2","key":"9611_CR36","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1176\/appi.ajp.2017.17040472","volume":"175","author":"ST Wilkinson","year":"2018","unstructured":"Wilkinson, S. T., Ballard, E. D., Bloch, M. H., Mathew, S. J., Murrough, J. W., Feder, A., Sos, P., Wang, G., Zarate, C. A., & Sanacora, G. (2018). The effect of a single dose of intravenous ketamine on suicidal ideation: A systematic review and individual participant data meta-analysis. American Journal of Psychiatry, 175(2), 150\u2013158. https:\/\/doi.org\/10.1176\/appi.ajp.2017.17040472","journal-title":"American Journal Of Psychiatry"},{"key":"9611_CR37","doi-asserted-by":"publisher","first-page":"1209419","DOI":"10.3389\/fpsyt.2024.1209419","volume":"15","author":"P Wolfson","year":"2024","unstructured":"Wolfson, P., & Vaid, G. (2024). Ketamine-assisted psychotherapy, psychedelic methodologies, and the impregnable value of the subjective-a new and evolving approach. Frontiers in Psychiatry, 15, 1209419. https:\/\/doi.org\/10.3389\/fpsyt.2024.1209419","journal-title":"Frontiers In Psychiatry"},{"key":"9611_CR38","doi-asserted-by":"publisher","first-page":"28817","DOI":"10.1038\/s41598-024-79931-w","volume":"14","author":"MJ Wood","year":"2024","unstructured":"Wood, M. J., McAlpine, R. G., & Kamboj, S. K. (2024). Strategies for resolving challenging psychedelic experiences: Insights from a mixed-methods study. Scientific Reports, 14, 28817. https:\/\/doi.org\/10.1038\/s41598-024-79931-w","journal-title":"Scientific Reports"},{"key":"9611_CR39","doi-asserted-by":"publisher","unstructured":"Zaki, N., Chen, L. (Nancy), Lane, R., Doherty, T., Drevets, W. C., Morrison, R. L., Sanacora, G., Wilkinson, S. T., Popova, V., & Fu, D. J. (2023). Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: Interim results of the SUSTAIN-3 study. Neuropsychopharmacology, 48(8):1225\u20131233. https:\/\/doi.org\/10.1038\/s41386-023-01577-5","DOI":"10.1038\/s41386-023-01577-5"},{"issue":"7604","key":"9611_CR40","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature17998","volume":"533","author":"P Zanos","year":"2016","unstructured":"Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016). NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature, 533(7604), 481\u2013486. https:\/\/doi.org\/10.1038\/nature17998","journal-title":"Nature"},{"key":"9611_CR41","doi-asserted-by":"publisher","first-page":"109219","DOI":"10.1016\/j.neuropharm.2022.109219","volume":"218","author":"J-C Zhang","year":"2022","unstructured":"Zhang, J-C., Yao, W., & Hashimoto, K. (2022). Arketamine, a new rapid-acting antidepressant: A historical review and future directions. Neuropharmacology, 218, 109219. https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109219","journal-title":"Neuropharmacology"},{"issue":"4","key":"9611_CR42","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1080\/20403313.2022.2082081","volume":"13","author":"YK Zhou","year":"2022","unstructured":"Zhou, Y. K. (2022). More on what it means to suffer harm. Jurisprudence, 13(4), 516\u2013544. https:\/\/doi.org\/10.1080\/20403313.2022.2082081","journal-title":"Jurisprudence"}],"container-title":["HEC Forum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10730-026-09611-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10730-026-09611-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10730-026-09611-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:30:10Z","timestamp":1788967810000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10730-026-09611-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":42,"alternative-id":["9611"],"URL":"https:\/\/doi.org\/10.1007\/s10730-026-09611-x","relation":{},"ISSN":["0956-2737","1572-8498"],"issn-type":[{"value":"0956-2737","type":"print"},{"value":"1572-8498","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"assertion":[{"value":"16 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is a conceptual ethics analysis and does not report original research involving human participants, animals, human tissues, or identifiable patient data.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Institutional ethics committee approval and informed consent were therefore not required.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}}]}}